226 related articles for article (PubMed ID: 24640740)
1. [Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
Khokhlova SV; Cherkasova MV; Orel NF; Limareva SV; Bazaeva IIa; Gorbunova VA
Vestn Ross Akad Med Nauk; 2013; (11):115-21. PubMed ID: 24640740
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of trabectedin in treating ovarian cancer.
Teplinsky E; Herzog TJ
Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
López-Guerrero JA; Romero I; Poveda A
Chin J Cancer; 2015 Jan; 34(1):41-9. PubMed ID: 25556617
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
[TBL] [Abstract][Full Text] [Related]
5. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin for the treatment of relapsed ovarian cancer.
Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
[TBL] [Abstract][Full Text] [Related]
7. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
Colombo N
Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S12-6. PubMed ID: 21540666
[TBL] [Abstract][Full Text] [Related]
10. Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.
Poveda A; Ray-Coquard I; Romero I; Lopez-Guerrero JA; Colombo N
Cancer Treat Rev; 2014 Apr; 40(3):366-75. PubMed ID: 24296108
[TBL] [Abstract][Full Text] [Related]
11. When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Colombo N
Future Oncol; 2017 Oct; 13(23s):23-29. PubMed ID: 29020821
[TBL] [Abstract][Full Text] [Related]
12. Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
Colombo N; Hardy-Bessard AC; Ferrandina G; Marth C; Romero I
Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):11-19. PubMed ID: 27797622
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
Sehouli J; Alfaro V; González-Martín A
Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
[TBL] [Abstract][Full Text] [Related]
14. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Giuliani J; Bonetti A
Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
[TBL] [Abstract][Full Text] [Related]
15. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
[TBL] [Abstract][Full Text] [Related]
17. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
Boccia SM; Sassu CM; Ergasti R; Vertechy L; Apostol AI; Palluzzi E; Fagotti A; Scambia G; Marchetti C
Drug Des Devel Ther; 2024; 18():2021-2032. PubMed ID: 38863768
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
Vertechy L; Boccia SM; Tiberi G; Avesani G; Corrado G; Fagotti A; Scambia G; Marchetti C
Int J Gynecol Cancer; 2023 Feb; 33(2):243-249. PubMed ID: 36564097
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Marth C
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
[TBL] [Abstract][Full Text] [Related]
20. Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.
Colombo N
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):13-17. PubMed ID: 30223694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]